A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

NCT00240253 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: pramlintide acetate

Sponsor

AstraZeneca